Jacobio Pharma Announces 2022 Annual Results
- Written by PR Newswire
![]() |
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment was RMB530 million, showing an increase of 26% compared with 2021. The revenue was RMB95.7 million, which was generated from an out-licensing deal. Jacobio Pharma also announced its recent...